



## **Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference**

December 30, 2020

WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 4:30 PM ET.

A live webcast of the presentation will be available on the Investor section of Morphic's website at [www.morphictx.com](http://www.morphictx.com). An archived replay will be available on the company's website following the conference.

### **About Morphic Therapeutic**

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit [www.morphictx.com](http://www.morphictx.com).

### **Contacts**

Morphic Therapeutic  
Chris Erdman  
[chris.erdman@morphictx.com](mailto:chris.erdman@morphictx.com)  
617.686.1718

Media Contact  
Adam Silverstein, Ten Bridge Communications  
[adam@tenbridgecommunications.com](mailto:adam@tenbridgecommunications.com)  
917.697.9313